An observational study in Colonic Adenomatous Polyp, sponsored by Valduce Hospital. Completed at 1 site in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Valduce Hospital · Observational
Recently, a CNN-based artificial intelligence (AI) system for polyp characterization has been developed by Fujifilm Co., Tokyo, Japan. It works in conjunction with BLI system. In the present study we prospectively evaluate whether the evaluation of the endoscopist combined with the CAD system output achieve > 90% accuracy in characterization (i.e. as adenomas or non-adenomas) of diminutive rectosigmoid polyps having histopathology as reference standard. Consecutive adult outpatients undergoing elective colonoscopy, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected are included. During endoscopic procedures all polyps identified by the endoscopist are documented for size, location and morphology. All diminutive polyps are characterized by a three sequential steps process: I) endoscopist prediction: the endoscopist evaluates the polyp by using BLI through the BASIC classification; the confidence level (high vs. low) in histology prediction is recorded; II) AI prediction: the AI system is switched on and the output of the automatic evaluation is recorded; this outcome is rated as stable or unstable, depending of the consistency over time of the outcome; III) combined prediction: a final classification is provided by endoscopist in light of the results of the first and of the second step; the confidence level is recorded. All polyps are resected and retrieved in separate jars and sent for pathology assessment. Only polyps characterized with high confidence will be included in the per-polyp analysis; the high-confidence characterization rate will be also calculated; the rate of polyps characterized with a CAD stable outcome will be calculated. Operative characteristics (sensitivity, specificity, positive and negative predictive value and accuracy) in distinguishing adenomatous from non-adenomatous polyps, evaluated with high confidence, will be calculated for each diminutive polyp and for each diminutive rectosigmoid polyp, having histopathology report as reference standard. The post-polypectomy surveillance intervals will be calculated on the basis of polyp histology (reference standard) in all patients according to both USMSTF and ESGE guidelines.
66 studies on the registry are indexed under Adenomatous Polyps; 8 are open to participants now.
This study's enrollment of 1,134 is above the median of 598 across 17 observational studies indexed under Adenomatous Polyps.
Browse Adenomatous Polyps studies →Valduce Hospital is the lead sponsor of 29 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive adult outpatients undergoing elective colonoscopy, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Consecutive adult (\>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected. Exclusion criteria: * patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer * patients with inadequate bowel preparation * patients in which caecal intubation was not achieved or scheduled for partial examinations * polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment * patients undergoing urgent colonoscopy.
Diagnostic Test: Polyp carachterization by combing endoscopist evaluation and Ai output
A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
Agreement of combined prediction with PIVI I statement
To prospectively evaluate whether the evaluation of the endoscopist combined with the CAD system output achieve \> 90% accuracy in characterization (i.e. as adenomas or non-adenomas) of diminutive rectosigmoid polyps (i.e. PIVI I threshold) having histopathology as reference standard.
Time frame: 6 months
Endoscopist prediction
to calculate the performance measures (sensitivity, specificity, positive and negative predictive value) of the endoscopist alone in characterizing diminutive rectosigmoid polyps
Time frame: 6 months
Ai prediction
- to calculate the performance measures (sensitivity, specificity, positive and negative predictive value) of the AI system alone in characterizing diminutive rectosigmoid polyps
Time frame: 6 months
Agreement of combined prediction with PIVI II statement
- to evaluate if the evaluation of the endoscopist combined with the CAD system output achieve \> 90% accuracy in the assignment of post-polypectomy surveillance intervals, according to US and EU guidelines, when combined with the histopathology assessment of polyps \>5 mm in size
Time frame: 6 months
Plan to share: No
Ran from Oct 2020 to primary completion in Feb 2021, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Valduce Hospital